DEXYANE MeD

Soothing repair cream

Medical device

DEXYANE MeD

Soothing repair cream

Medical device Treats eczema lesions - Repairs - Soothes

A medical device that treats and limits the recurrence of atopic, contact eczema lesions including chronic eczema of the hands.

  • DEXYANE MED Soothing repair cream can be used as a stand-alone treatment, in combination with/ or as a follow-up to topical corticosteroids to treat and limit the recurrence of eczema lesions.
  • Treats and limits the recurrence of eczema lesions. Tested under dermatological control.

Usable by Babies - Children - Teenagers - Adults

Suitable Body - face - hands

Skin type Dry skin prone to atopic eczema - Eczema

Need Anti-eczema

Made in France

Dexyane Med cream* is a medical device indicated for treatment of atopic and contact eczema, including chronic eczema of the hands.
The skin is protected : its pleasant texture forms a semi-occlusive film on the surface.

Benefits

• USE alone, in combination with/or in conjunction with topical corticosteroids.
• PROTECTS the skin thanks to its pleasant texture which forms a semi-occlusive film on the surface.

*Dexyane Med Cream is a medical device indicated for treatment of atopic and contact eczema, including chronic eczema of the hands. Eczema conditions are characterized by an altered skin barrier with a higher risk of reaction (dryness, irritations, itching) to allergens and irritant agents. Read carefully the instructions for use before utilisation. Ask your pharmacist for advice. Conditions of availability and instructions for use may vary per country. CE marking 0459. Manufacturer: PIERRE FABRE MEDICAMENT, Les Cauquillous, 81500 LAVAUR, FRANCE.

*DEXYANE MED Soothing repair cream is a class CE medical device. Carefully read the instruction leaflet provided. Do not use if pregnant or breastfeeding. Do not use on the mucous membranes or on the nappy area of children still in nappies. Avoid all direct contact with eyes. Ages 3 months and up. Manufacturer: Pierre Fabre Medicament.

The Green Impact Index is a tool displaying the environmental and societal impact of cosmetics, dietary supplements and wellness and family health products, based on the methodology of the AFNOR Spec 2215. Developed thanks to the contribution of 22 companies, associations and federations, it assesses your products on more than 50 criteria for ever greater transparency!

Understanding the Green Impact Index

Green impact index: C

Environmental impact

Formula

Note Formula : B

Biodegradable formula*
85.0% natural origin ingredients
*According to a OECD 301 test or Biodegradability index method

Packaging

Note Packaging : C

Not recyclable packaging

Manufacturing

Note Manufacturing : B

Made and packaged in a factory certified for the environment***
***according to ISO 14001 and/or 50001 standards

Transportation

Note Transportation : D

Societal impact

Societal impact

Note Societal impact : B

Product manufactured and packaged in a factory meeting French social standards
Ducray is a brand of the Pierre Fabre Group, certified at the highest Exemplary level of AFNOR Certification’s Committed to CSR and Responsibility Europe labels, thus consolidating a long-standing commitment to contributing to sustainable development.

Application

Frequency of use

2 times a day

•Apply directly to inflammatory eczema lesions, twice a day.
•Can be use as stand-alone treatment, in combination with or following topical corticosteroids
•When combined with a topical corticosteroid, apply the topical corticosteroid and wait a few minutes (5-15 minutes) before applying DEXYANE MED Cream.

Precautions to use :
• Do not use if you are allergic to one of the ingredients
• If you experience an allergic reaction, consult a doctor
• Avoid contact with the eyes to prevent irritation
• In case of contact with eyes, rinse immediately with clean water
• If eye irritation persists, consult a doctor.
• Do not use if pregnant or breastfeeding.
• Keep out of reach of children
• Do not use on the infants' diaper area or on mucosae.
• Do not exceed 30% of the body surface
• Close the tube carefully after use
• If you experience any side effects as a result of using the product, consult a doctor.
•Cutaneous application site reactions (burning sensation, stinging, erythema, itching, dryness...) are expected in subjets with eczema because these subjects present an altered skin barrier. It is possible to observe a temporary aggravation of eczema.
•If no improvement or in case of worsening of eczema symptoms within 8 to 10 days, consult a doctor.
•If any doubt and/or any undesirable side effects linked to the use of this product, consult a doctor.
•If you have a reason to believe that a serious incident occured linked to the use of the product, please report it to your national authority ant to the manufacturer.

Ingredients

AQUA. GLYCERIN. CAPRYLIC/CAPRIC TRIGLYCERIDE. BUTYLENE GLYCOL. POLYSORBATE 60. GLYCERYL STEARATE. BUTYROSPERMUM PARKII (SHEA) BUTTER. CERA ALBA. PEG-100 STEARATE. 10-HYDROXYDECENOIC ACID. CAPRYLYL GLYCOL. CETYL ALCOHOL. CITRIC ACID. GLYCYRRHETINIC ACID. GUANIDINE CARBONATE. POLYACRYLATE-13. POLYISOBUTENE. POLYSORBATE 20. SCLEROTIUM GUM. SORBITAN ISOSTEARATE

The consumer is advised to systematically check the composition of the product before purchasing it.

Results

• Helps eliminate eczema lesions and limits recurrence.
• Significant improvement in the clinical signs after 3 days of applying DEXYANE MED in combination with topical corticosteroids¹.

    ¹Result of a comparative clinical study conducted on 54 adults with moderate to severe atopic dermatitis on the arms or behind the knees (moderate to severe symmetrical lesions). Product applied twice a day in combination with a medium potency topical corticosteroid on one limb and application of the topical corticosteroid alone on the other limb, for 10 days; then followed by 2 weeks without corticosteroid.
    The objective was to evaluate the benefit of the association compared to topical corticosteroid alone in the improvement of atopic dermatis in adults at Day 3 (measured by L-SCORAD).
    Results: At D3, 8.9 without Dexyane Med versus 7.7 with Dexyane Med (p= 0.0005).
    Loading...